Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Many users report feeling more capable and confident as their physical capacity expands alongside weight loss
Semaglutide (Wegovy, Ozempic) aims at one receptor (GLP-1), while tirzepatide (Zepbound, Mounjaro) homes in on two (GLP-1 and GIP)
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
Research into MOTS-c has illuminated its critical role in maintaining metabolic homeostasis
Efficacy: Semaglutide has superior reductions in HbA1c and body weight compared to other agents, while tirzepatide, a dual GLP-1/GIP receptor agonist, shows even greater efficacy but with higher rates of adverse events
The obesity pharmacotherapy landscape shifted dramatically when Phase 2 data for Retatrutide emerged in 2023
US$ 20.35
US$ 20.86
US$ 21.98
US$ 22.55
US$ 21.46
US$ 27.90
US$ 29.20
US$ 28.23
